The Genitourinary Oncology Program Area is composed of 18 members, spanning 9 Departments within UCLA. In the past competing cycle, investigators from this Program authored 328 publications, of which 167 (51%) were inter-programmatic and 190 (58%) intra-programmatic. 96 (29%) were placed in high-impact ournals. 11 members of this Program Area used 8 out of the 8 JCCC Shared Resources. Peer-reviewed Funding for this program totals $8.7M of which $4.3M is awarded from NCI. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the GU Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the GU Program Area total $1,001,382. These funds supported Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support. ($500K of these funds were in support of the UCLA Prostate SPORE. These funds were then used to support SPORE-related activities which benefited a larger group of faculty, some of whom are JCCC Members.) The Program seeks to coordinate all clinical activities to deliver optimum care to patients with localized and metastatic tumors. Furthermore, the Program hopes to facilitate the study of new and emerging treatment strategies, especially those translated from basic science research. The goals of the GU Oncology Program are: 1) Creating mouse models of these cancers;2) Perform pre-clinical studies of new therapeutic agents; and 3) Conduct phase l/ll clinical trials of novel anti-cancer drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016042-38
Application #
8392127
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
38
Fiscal Year
2013
Total Cost
$144,993
Indirect Cost
$66,161
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Yu, Jingyi; Seldin, Marcus M; Fu, Kai et al. (2018) Topological Arrangement of Cardiac Fibroblasts Regulates Cellular Plasticity. Circ Res 123:73-85
Hong, Aayoung; Moriceau, Gatien; Sun, Lu et al. (2018) Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov 8:74-93
Epeldegui, Marta; Magpantay, Larry; Guo, Yu et al. (2018) A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma. AIDS 32:945-954
Hsu, Jeffrey J; Lu, Jinxiu; Umar, Soban et al. (2018) Effects of teriparatide on morphology of aortic calcification in aged hyperlipidemic mice. Am J Physiol Heart Circ Physiol 314:H1203-H1213
Woo, Jin Seok; Srikanth, Sonal; Kim, Kyun-Do et al. (2018) CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses. J Immunol 201:1174-1185
Patananan, Alexander N; Sercel, Alexander J; Teitell, Michael A (2018) More than a powerplant: the influence of mitochondrial transfer on the epigenome. Curr Opin Physiol 3:16-24
Heard, Jeffrey J; Phung, Ivy; Potes, Mark I et al. (2018) An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer 18:69
Kim, Roy Y; Mangu, Darian; Hoffman, Alexandria S et al. (2018) Oestrogen receptor β ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis. Brain 141:132-147
Pothoulakis, Charalabos; Torre-Rojas, Monica; Duran-Padilla, Marco A et al. (2018) CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis. Int J Cancer 142:334-346
Montecino-Rodriguez, Encarnacion; Casero, David; Fice, Michael et al. (2018) Differential Expression of PU.1 and Key T Lineage Transcription Factors Distinguishes Fetal and Adult T Cell Development. J Immunol 200:2046-2056

Showing the most recent 10 out of 767 publications